172 related articles for article (PubMed ID: 16862527)
1. Composition, quality control, and labeling of plasma-derived products for the treatment of von Willebrand disease.
Mazurier C
Semin Thromb Hemost; 2006 Jul; 32(5):529-36. PubMed ID: 16862527
[TBL] [Abstract][Full Text] [Related]
2. Von Willebrand factor/factor VIII concentrates in the treatment of von Willebrand disease.
Batlle J; López-Fernández MF; Fraga EL; Trillo AR; Pérez-Rodríguez MA
Blood Coagul Fibrinolysis; 2009 Mar; 20(2):89-100. PubMed ID: 19786936
[TBL] [Abstract][Full Text] [Related]
3. The factor VIII/von Willebrand factor complex: basic and clinical issues.
Federici AB
Haematologica; 2003 Jun; 88(6):EREP02. PubMed ID: 12826528
[TBL] [Abstract][Full Text] [Related]
4. Comparative analysis and classification of von Willebrand factor/factor VIII concentrates: impact on treatment of patients with von Willebrand disease.
Budde U; Metzner HJ; Müller HG
Semin Thromb Hemost; 2006 Sep; 32(6):626-35. PubMed ID: 16977573
[TBL] [Abstract][Full Text] [Related]
5. PFA-100 monitoring of von Willebrand factor (VWF) responses to desmopressin (DDAVP) and factor VIII/VWF concentrate substitution in von Willebrand disease type 1 and 2.
van Vliet HH; Kappers-Klunne MC; Leebeek FW; Michiels JJ
Thromb Haemost; 2008 Sep; 100(3):462-8. PubMed ID: 18766263
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the pharmacokinetics of two von Willebrand factor concentrates [Biostate and AHF (High Purity)] in people with von Willebrand disorder. A randomised cross-over, multi-centre study.
Favaloro EJ; Lloyd J; Rowell J; Baker R; Rickard K; Kershaw G; Street A; Scarff K; Barrese G; Maher D; McLachlan AJ
Thromb Haemost; 2007 Jun; 97(6):922-30. PubMed ID: 17549293
[TBL] [Abstract][Full Text] [Related]
7. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.
Michiels JJ; van Vliet HH; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van der Velden A; Budde U
Clin Appl Thromb Hemost; 2007 Jan; 13(1):14-34. PubMed ID: 17164493
[TBL] [Abstract][Full Text] [Related]
8. Guidelines for the evaluation of intravenous desmopressin and von Willebrand factor/factor VIII concentrate in the treatment and prophylaxis of bleedings in von Willebrand disease types 1, 2, and 3.
Michiels JJ; Gadisseur A; van der Planken M; Schroyens W; van de Velden A; Berneman Z
Semin Thromb Hemost; 2006 Sep; 32(6):636-45. PubMed ID: 16977574
[TBL] [Abstract][Full Text] [Related]
9. A systematic overview of the first pasteurised VWF/FVIII medicinal product, Haemate P/ Humate -P: history and clinical performance.
Berntorp E; Archey W; Auerswald G; Federici AB; Franchini M; Knaub S; Kreuz W; Lethagen S; Mannucci PM; Pollmann H; Scharrer I; Hoots K
Eur J Haematol Suppl; 2008 May; (70):3-35. PubMed ID: 18380871
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of a high purity, double virus inactivated factor VIII/von Willebrand factor concentrate (Biostate) in patients with von Willebrand disorder requiring invasive or surgical procedures.
Shortt J; Dunkley S; Rickard K; Baker R; Street A
Haemophilia; 2007 Mar; 13(2):144-8. PubMed ID: 17286766
[TBL] [Abstract][Full Text] [Related]
11. Managing patients with von Willebrand disease type 1, 2 and 3 with desmopressin and von Willebrand factor-factor VIII concentrate in surgical settings.
Michiels JJ; van Vliet HH; Berneman Z; Schroyens W; Gadisseur A
Acta Haematol; 2009; 121(2-3):167-76. PubMed ID: 19506363
[TBL] [Abstract][Full Text] [Related]
12. Management of inherited von Willebrand disease in 2006.
Federici AB
Semin Thromb Hemost; 2006 Sep; 32(6):616-20. PubMed ID: 16977571
[TBL] [Abstract][Full Text] [Related]
13. The von Willebrand disease prophylaxis network (vWD PN): exploring a treatment concept.
Berntorp E; Abshire T;
Thromb Res; 2006; 118 Suppl 1():S19-22. PubMed ID: 16545435
[TBL] [Abstract][Full Text] [Related]
14. Time to think outside the box? Proposals for a new approach to future pharmacokinetic studies of von Willebrand factor concentrates in people with von Willebrand disease.
Favaloro EJ; Kershaw G; McLachlan AJ; Lloyd J
Semin Thromb Hemost; 2007 Nov; 33(8):745-58. PubMed ID: 18175280
[TBL] [Abstract][Full Text] [Related]
15. Highly purified VWF/FVIII concentrates in the treatment and prophylaxis of von Willebrand disease: the PRO. WILL Study.
Federici AB
Haemophilia; 2007 Dec; 13 Suppl 5():15-24. PubMed ID: 18078393
[TBL] [Abstract][Full Text] [Related]
16. Plasma-derived biological medicines used to promote haemostasis.
Ofosu FA; Freedman J; Semple JW
Thromb Haemost; 2008 May; 99(5):851-62. PubMed ID: 18449414
[TBL] [Abstract][Full Text] [Related]
17. Restoration of plasma von Willebrand factor deficiency is sufficient to correct thrombus formation after gene therapy for severe von Willebrand disease.
De Meyer SF; Vandeputte N; Pareyn I; Petrus I; Lenting PJ; Chuah MK; VandenDriessche T; Deckmyn H; Vanhoorelbeke K
Arterioscler Thromb Vasc Biol; 2008 Sep; 28(9):1621-6. PubMed ID: 18556568
[TBL] [Abstract][Full Text] [Related]
18. Recessive von Willebrand disease type 2 Normandy: variable expression of mild hemophilia and VWD type 1.
Michiels JJ; Gadisseur A; Vangenegten I; Schroyens W; Berneman Z
Acta Haematol; 2009; 121(2-3):119-27. PubMed ID: 19506358
[TBL] [Abstract][Full Text] [Related]
19. Prophylaxis in von Willebrand disease.
Berntorp E
Haemophilia; 2008 Nov; 14 Suppl 5():47-53. PubMed ID: 18786010
[TBL] [Abstract][Full Text] [Related]
20. Clinical efficacy in bleeding and surgery in von Willebrand patients treated with Fanhdi a highly purified, doubly inactivated FVIII/VWF concentrate.
Hernandez-Navarro F; Quintana M; Jimenez-Yuste V; Alvarez MT; Fernandez-Morata R
Haemophilia; 2008 Sep; 14(5):963-7. PubMed ID: 18624696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
